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Post-translational conversion of arginine to citrulline residues is catalyzed by peptidylarginine deiminases (PAD).
Although the existence of ﬁve isoforms of PAD has been reported in rodents and humans, their tissue distribution,
substrate speciﬁcity, and physiological function have yet to be explored. In the epidermis, deimination of ﬁlaggrin
and keratins is involved in maintaining hydration of the stratum corneum (SC), and hence the cutaneous barrier
function. Here, RT-PCR, western blotting, and confocal microscopy analyses with anti-peptide antibodies highly
specific for each of the PAD1–4 demonstrated that only PAD1–3 are expressed in mouse and human epidermis.
PAD1 was detected in all layers, including the SC, and PAD2 in all the living layers, whereas PAD3 expression was
shown to be restricted to the granular layer and lower SC. Moreover, PAD1 and 3 were observed to co-localize with
(pro)ﬁlaggrin, and PAD2 to be located at the keratinocyte periphery in the stratum granulosum. We also detected
PAD1 in extracts of superﬁcial SC, where K1 is deiminated. Moreover, we showed that PAD1 and 3 are able to
modify ﬁlaggrin in vitro. These data strongly suggest that each enzyme exerts a specific role in the course of
epidermis differentiation.
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Peptidylarginine deiminases (PAD) (protein–arginine deimi-
nase, protein–L-arginine iminohydrolase, EC 3.5.3.15) are
post-translational modification enzymes that convert the
guanidino group of arginine in proteins to the ureido group
of citrulline, in a Ca2þ -dependent manner (Fujisaki and
Sugawara, 1981; Sugawara et al, 1982; Vossenaar et al,
2003). A family of five conserved PAD isoforms (PAD1–6)
has been identified in various tissues of vertebrates and are
encoded by five genes, clustered on chromosome 1p35–36
in humans. PAD1 has mainly been detected in the epidermis
and uterus, although mRNA expression data suggest a
broader tissue distribution (Terakawa et al, 1991; Ishigami
et al, 1998; Rus’d et al, 1999; Guerrin et al, 2003). PAD2 is
widely expressed and is particularly abundant in the skeletal
muscle, brain, uterus, salivary glands, and pancreas
(Takahara et al, 1989; Watanabe and Senshu, 1989; Aki-
yama et al, 1990; Terakawa et al, 1991; Ishigami et al, 2002).
PAD3 is known to be expressed in hair follicles and in rodent
epidermis (Terakawa et al, 1991; Nishijyo et al, 1997; Rogers
et al, 1997; Rus’d et al, 1999; Kanno et al, 2000). PAD4
(formerly known as PAD5) is found primarily in hemato-
poietic cells (Nakashima et al, 1999; Asaga et al, 2001;
Vossenaar et al, 2004). Human PAD6 mRNA were detected
by RT-PCR in the ovary, peripheral blood leukocytes, and
testis, and, at minor levels, in the small intestine, spleen,
lung, liver, and skeletal muscle (Chavanas et al, 2004). The
latest isoform was also identified from mouse eggs by a
proteomic approach and named ePAD (Wright et al, 2003).
Although their exact physiological functions are not
known, PAD have been suggested to play important roles
in several human diseases. Indeed, an increased deimination
of myelin basic protein and glial fibrillary acidic protein (Kim
et al, 2003; Nicholas et al, 2004) is involved in the patho-
genesis of multiple sclerosis. In rheumatoid arthritis, disease-
associated circulating autoantibodies to citrullinated proteins
recognize deiminated fibrin extracted from patient synovial
membranes, and are suspected to contribute to the joint in-
flammation (Girbal-Neuhauser et al, 1999; Masson-Bessie`re
et al, 2001). Furthermore, a recent study revealed the asso-
ciation in a Japanese population between functional haplo-
types of the PADI4 gene and rheumatoid arthritis (Suzuki
et al, 2003). Alterations in the pattern of deiminated epider-
mal proteins have been reported in some skin disorders,
namely psoriasis and bullous congenital ichthyosiform er-
ythroderma (Ishida-Yamamoto et al, 2000, 2002), suggesting
a crucial role of PAD during the late stages of epidermal
differentiation. Lastly, deimination of histones was observed
in granulocytes, suggesting a role in chromatin remodelling
(Hagiwara et al, 2002; Nakashima et al, 2002).
Abbreviations: DSG, desmoglein; IF, immunofluorescence; MoAb,
monoclonal antibody; PAD, peptidylarginine deiminase; PAGE,
polyacrylamide gel electrophoresis; SC, stratum corneum; SDS,
sodium dodecyl sulfate; STI, soybean trypsin inhibitor
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Using an antiserum that detects chemically modified
citrulline residues independent of the surrounding amino
acid sequences, deiminated proteins were detected in the
stratum corneum (SC) (Senshu et al, 1995, 1996). Keratin K1
was identified as the major deiminated epidermal protein,
K10 and the intermediate filament-associated protein filag-
grin as the minor ones (Senshu et al, 1996). Deimination of
the three proteins leads to a drastic charge loss inducing
the disassembly of filaggrin from the keratin intermediate
filaments (Senshu et al, 1999b). Then, breakdown of filag-
grin to free amino acids occurs. These amino acids would
be involved in maintaining a proper hydration of the SC
necessary for the barrier function of the skin (Rawlings and
Harding, 2004).
In human adult epidermis, we detected PAD1 in the cy-
toplasm of all the nucleated keratinocytes with a higher level
in the upper spinous and granular layers (Guerrin et al,
2003), and we demonstrated that PAD6 is not expressed
(Chavanas et al, 2004). No clear data, however, are available
about the expression pattern of the other PAD. Moreover,
although PAD1 has been proposed to be responsible for K1
deimination (Senshu et al, 1999a), which PAD are involved in
the modification of filaggrin and K10 is not known.
To gain more information on the physiological role of PAD
in the epidermis, we describe in this paper their expression
pattern using affinity-purified anti-peptide antibodies highly
specific for each isoform in western blotting and confocal
laser microscopy analysis.
Results
Analysis of PADImRNA expression in human tissues In
our previous papers, PADI1 tissue distribution was charac-
terized by RT-PCR as major in the placenta, prostate, testis,
thymus, and epidermis, and PADI6 in the ovary (Guerrin
et al, 2003; Chavanas et al, 2004). In this work, the ex-
pression of PADI2–4 in human adult tissues was also
investigated by RT-PCR (Fig 1). PADI2 was found to be
transcribed in all samples tested, including the skin, epi-
dermis, and HL-60 cells. PADI3 showed a more restricted
expression profile, in the colon, prostate, small intestine,
testis, thymus, lung, kidney, pancreas, skin, epidermis, and
HL-60 cells. PADI4 mRNA also seems to be expressed in a
large panel of tissues with higher levels in peripheral blood
leukocytes and spleen, intermediate levels in the prostate,
small intestine, testis, heart, placenta, lung, and liver and
lower levels in the thymus, kidney, and pancreas. By con-
trast, PADI4 cDNA was not amplified from human adult
epidermis. With respect to skin, PADI4 cDNA was found to
be transcribed in only one of three different samples. In HL-
60 cells, besides PADI2–4, we were also able to detect the
expression of PADI6 but not of PADI1 (data not shown).
Production of highly specific anti-PAD antibodies To
explore the expression in the epidermis of PAD at the protein
level, anti-peptide antibodies were developed against
PAD1–4, only these four isoforms being known when we
started work. To design isoform-specific potentially immu-
nogenic peptides, multi-alignment of the human, mouse,
and rat PAD sequences was performed. For each PAD, three
peptides identified in the most differential regions, but which
were also orthologous conserved regions, were synthesized
and used for immunizing rabbits (Tables I and III). The anti-
PAD1 serum has been described previously (Guerrin et al,
2003). The specificity of the anti-PAD2 and anti-PAD3 an-
tisera was extensively checked. The antisera were first test-
ed by ELISA on their corresponding synthetic peptides (data
not shown). The anti-PAD2 serum reacted strongly with the
Figure 1
Expression of peptidylarginine deiminase transcripts (PADI2–4) in
adult human tissues. cDNAs from 18 different human tissues or or-
gans, and from HL-60 cells, as indicated at the top of the figure were
analyzed by PCR using PADI2–4-, and glyceraldehyde 3-phosphate
dehydrogenase (G3PDH)-specific oligonucleotides. The figure corre-
sponds to results representative of several independent experiments
performed on different batches of cDNA. For each individual organ or
tissue shown, G3PDH and PADI transcripts were analyzed at the same
time on the same batch to yield comparable results. The vertical black
lines indicate data sets obtained in separate experiments. Sizes are
shown at the right side in bp. The expected size of each PCR product is
indicated on the right. PBL, peripheral blood leukocytes; small int.,
small intestine; Sk. muscle, skeletal muscle.
Table I. Antibodies used for immunoblotting and/or
immunohistology
Antibodies
Speciﬁcity
(peptides used
in puriﬁcation)
Source,
reference
Affinity-purified anti-peptide antibodies
Anti-PAD1 Human PAD1
(peptides A1, B1, C1)
Guerrin et al (2003)
Anti-PAD2 Human PAD2
(peptides A2, B2, C2)
This work
Anti-PAD2 (C2) Human PAD2
(peptide C2)
Anti-PAD3 Human PAD3
(peptides A3, B3, C3)
This work
Anti-PAD3 (B3) Human PAD3
(peptide B3)
Anti-PAD4 Human PAD4
(peptides A4, B4, C4)
This work
Monoclonal antibodies
AHF3 Human (pro)filaggrin Simon et al (1995)
AHF5 Human (pro)filaggrin Simon et al (1995)
DG3.10 Human DSG1 and
DSG2
Progen Biotechnik
GmbH
PAD, peptidylarginine deiminase isoforms; DSG, desmoglein.
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peptide corresponding to residues 514–527 (peptide C2).
The anti-PAD3 serum predominantly reacted with the pep-
tide corresponding to residues 49–66 (peptide B3). The anti-
PAD4 serum presented a high reactivity against the three
PAD4-derived peptides. The antisera were then purified by
affinity chromatography on a mixture of their corresponding
three peptides. Competition immunoblotting experiments
showed a dramatic or complete loss of immunoreactivity of
the affinity-purified anti-PAD2, anti-PAD3, and anti-PAD4
antibodies after adsorption with peptides C2, B3, and B4,
respectively (Fig 2A). Moreover, the proteins were not de-
tected when non-immune sera were used (data not shown).
Based on these results, the anti-PAD2 and anti-PAD3 sera
were affinity-purified on peptides C2 and B3, respectively.
The anti-peptide antibodies obtained were named anti-PAD2
(C2) and anti-PAD3 (B3).
We then investigated the cross-reactivity of each affinity-
purified anti-PAD antibody to the other PAD isoforms, in-
cluding PAD6. Recombinant GST-PAD1, PAD3, PAD4, and
PAD6, and purified rabbit muscle PAD2 were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and analyzed by western blotting (Fig 2B). The
anti-PAD1, anti-PAD2 (C2), anti-PAD3 (B3), and anti-PAD4
antibodies were shown to be highly specific for their respec-
tive PAD isoform. A recombinant human PAD2 was also only
detected by the anti-PAD2 (C2) antibodies (data not shown).
Expression of PAD isoforms in human epidermis When
an extract of human epidermis homogenized in a detergent-
containing buffer (TE-NP40 buffer extract) was immuno-
blotted with the anti-PAD1, anti-PAD2 (C2), and anti-PAD3
(B3) antibodies, immunoreactive bands corresponding to
human PAD1–3 were observed as 70, 76, and 70 kDa pro-
teins, respectively (Fig 3A). The reactivities disappeared
after adsorption of the antibodies on the corresponding
peptides. Confirming the RT-PCR results, PAD4 was not
detected in the human epidermis extract and was observed
as a 70 kDa protein in an HL-60 cell extract.
To enrich the epidermal extract in PAD, it was applied to
a column of soybean trypsin inhibitor (STI), a substrate of
PAD, immobilized on agarose. Each fraction of the affinity
chromatography was then analyzed by immunoblotting with
the anti-PAD antibodies (Fig 3B). PAD1 and 2 were shown to
be eluted from the affinity column in high amounts (lanes 8
and 9). PAD3 was only detected in the unbound protein
Figure 2
Affinity-purified anti-peptidylarginine deimi-
nase isoforms (PAD) antibodies are monospe-
cific. (A) Purified rabbit muscle PAD2, purified
recombinant PAD3, and a bacterial extract con-
taining PAD4 were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotted without any rabbit
antiserum (asterisk), and with the anti-PAD2, the
anti-PAD3, and the anti-PAD4 antibodies pre-
adsorbed (þ ) or not () with their corresponding
peptides, as indicated. (B) Recombinant human
GST-PAD1, PAD3, PAD4, PAD6, and purified rab-
bit muscle PAD2 were separated by SDS-PAGE
and immunoblotted with the anti-PAD1, anti-
PAD2 (C2), anti-PAD3 (B3), and anti-PAD4 anti-
bodies, as indicated. The position of molecular
mass markers is indicated on the left.
Figure3
Immunodetection of peptidylarginine deiminase isoforms (PAD)1–3
in human epidermis extracts. (A) Forty micrograms of proteins from
human epidermis and HL-60 cell extracts were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotted without any rabbit antiserum (asterisk) with the anti-
PAD1, the anti-PAD2 (C2), the anti-PAD3 (B3), and the anti-PAD4 an-
tibodies pre-adsorbed (þ ) or not () with the corresponding peptides,
as indicated. The position of molecular mass markers is indicated on
the left. (B) A human epidermis extract was loaded onto a soybean
trypsin inhibitor-agarose column. After washing in 10 mM CaCl2, ad-
sorbed proteins were eluted with 10 mM EGTA. The total extract, the
unbound (lanes 2–5), and eluted (lanes 6–13) proteins were collected,
separated by SDS-PAGE, and immunoblotted with the anti-PAD1, anti-
PAD2 (C2), and anti-PAD3 (B3) antibodies.
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fractions (lanes 2–4), whereas PAD4 was not detected (data
not shown).
To analyze the solubility properties of PAD1–3 and to
confirm the absence of expression of PAD4, the human
epidermis was sequentially extracted first in TE-NP40 buff-
er, then in the presence of urea and finally in the presence of
a reducing agent. Extracted proteins were separated by
SDS-PAGE and analyzed by immunoblotting with the anti-
PAD antibodies. PAD1–3 were only detected in the TE-NP40
buffer extract. Once again, PAD4 was not detected (data
not shown).
When total extracts of superficial SC from six normal
volunteers were immunoblotted using the anti-PAD anti-
bodies (Fig 4), an immunoreactive band of 70 kDa, corre-
sponding to PAD1, was detected with a variable intensity
between samples. By contrast, PAD2 and 3 were not de-
tected.
Localization of PAD1–3 in human epidermis Indirect
immunofluorescence (IF) on unfixed cryosections of normal
human skin allowed us to localize PAD1–3 in the human
epidermis. We performed double-label IF stainings and
confocal analysis, using the anti-PAD1, anti-PAD2 (C2), and
anti-PAD3 (B3) antibodies, and two monoclonal antibody
(MoAb) directed to either the desmosomal cadherins des-
moglein 1 and 2 (DSG1 and DSG2) (DG3.10) or (pro)filaggrin
(AHF3).
On control sections incubated in the absence of primary
antibody, no significant immunoreactivity was observed
(data not shown). DG3.10 produced pericellular labelling in
basal, spinous, and granular layers (Figs 5A, 6A, and 7A), as
expected. AHF3 showed strong cytoplasmic staining of the
stratum granulosum and diffuse staining of the lower SC
(Fig 5E, 6E, and 7E ) as described previously (Simon et al,
1995). The cytoplasmic location of PAD1 in keratinocytes of
all living epidermis layers, and the higher staining intensity in
the granular layer, previously observed using an epifluores-
cence microscope (Guerrin et al, 2003), was confirmed by
confocal microscopy (Fig 5B–D and F–H ). Moreover, a
granular pattern was clearly observed in the cytoplasm of
the granular layer keratinocytes (Fig 5D and H ). The double-
label IF staining combining anti-PAD1 and AHF3 antibodies
indicates the co-location of PAD1 and (pro)filaggrin in the
granular layer (Fig 5G and H ).
PAD2 was localized in the cytoplasm of keratinocytes of
all living epidermis layers, with a gradient of expression in-
creasing from the basal (very low level of detection) to the
granular layer (Fig 6B). Furthermore, intense pericellular la-
belling was observed in the granular layer (Fig 6B–D and H ).
Double staining, performed with anti-PAD2 (C2) and AHF3
antibodies, confirmed the apparent accumulation of PAD2
at the keratinocyte periphery and showed a rare co-location
of the two proteins (Fig 6G and H ).
PAD3 was only immunodetected in the granular layer and
lower SC (Fig 7B–D and F–H ), and cytoplasmic location
was observed at a high magnification (Fig 7H ). Double
staining using anti-PAD3 (B3) and AHF3 antibodies revealed
a convincing co-location of PAD3 with (pro)filaggrin in the
granular layer and in the lower SC (Fig 7G and H ).
Expression and location of PAD isoforms in mouse ep-
idermis The anti-PAD antibodies were used to analyze PAD
expression in epidermis extracts of adult B6/CBA mice. In a
TE-NP40 buffer extract, immunoreactive bands of 76 kDa,
corresponding to mouse PAD1 and 2, and of 80 kDa, cor-
responding to the mouse PAD3 (Fig 8A), were observed. In
agreement with the results obtained with human epidermis,
PAD4 was not detected in the mouse epidermis extracts.
To determine the PAD location in mouse epidermis,
immunohistochemical studies were performed on unfixed
Figure 4
Immunodetection of peptidylarginine deiminase isoforms (PAD)1
but not PAD2 and 3 in superficial stratum corneum (SC) extracts.
Superficial SC obtained by tape stripping from six different volunteers
(lanes 1–6) was solubilized in the presence of sodium dodecyl sulfate
(SDS) and dithiothreitol. Equal amounts of extracted proteins (40 mg)
were separated by SDS-polyacrylamide gel electrophoresis and
immunoblotted with the anti-PAD1, anti-PAD2 (C2), and anti-PAD3
(B3) antibodies.
Figure 5
Immunofluorescence staining of peptidylargi-
nine deiminase isoform (PAD)1 in human ep-
idermis. Normal human skin cryosections were
analyzed by confocal microscopy using the anti-
PAD1 antibodies, the anti-desmoglein 1 and 2
(DSG1—2) monoclonal antibody, DG3.10, and the
anti-(pro)filaggrin monoclonal antibody, AHF3, as
indicated. Image superimpositions of DSG1–2/
PAD1 and pro(filaggrin)/PAD1 are shown. Scale
bar: 40 mm (E–G), 20 mm (A–C), 10 mm (D and H).
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cryosections of newborn mouse skin (Fig 8B). Anti-PAD1
antibodies stained the stratum granulosum with a weaker
reaction on the lower SC of the epidermis. Anti-PAD2 (C2)
antibodies decorated the upper layers with intense and
pericellular labelling in the granular layer. Anti-PAD3 (B3)
antibodies showed intense cytoplasmic and granular stain-
ing of the granular keratinocytes. Very similar results were
obtained on sections of Bouin’s fixed skin, except with the
anti-PAD2 (C2) antibodies, which do not react on fixed skin
(data not shown).
Filaggrin deimination by recombinant human PAD1 and
3 The observed co-location of (pro)filaggrin and PAD1 and
3 suggested that these enzymes are involved in the deimi-
nation of filaggrin. To test this hypothesis, we looked at the
ability of these two enzymes to deiminate human epidermal
filaggrin in vitro. When a filaggrin-enriched extract of epi-
dermis was incubated in the presence of each enzyme, a
shift in the migration of filaggrin was induced indicating its
deimination (Fig 9). Indeed, such a shift is characteristic of
the deimination of several proteins, including filaggrin
(Tarcsa et al, 1996; Kanno et al, 2000).
Discussion
The first aim of this study was to complete our previously
published data concerning the transcription of PADI genes
in human adult tissues. Except for the brain, where only
PADI2 mRNA was detected, all tissues or organs tested
simultaneously expressed at least two PADI genes. PADI2
is the most widely expressed PADI gene. PADI3 mRNA
expression is not as restricted as generally thought; in par-
ticular, it is not specific to skin and hairs. PADI4 was found
to be expressed in a very large panel of tissues, probably
because it is highly expressed in blood cells. Furthermore,
our results demonstrate that HL-60 cells not only expressed
PADI4 mRNA, as previously reported (Nakashima et al,
1999), but also PADI2, 3, and 6. This suggests that hem-
atopoietic cells also express these isoforms. These data will
be confirmed at the protein level, since PAD expression was
reported to be regulated in hematopoietic cells at the tran-
scriptional but also at the translational level (Vossenaar et al,
2004).
The main purpose was to identify the different PAD iso-
forms expressed in the epidermis using anti-peptide anti-
bodies highly specific to each isoform. Our results clearly
demonstrate, both at the mRNA and protein level, that only
three PAD are expressed in healthy human and mouse ep-
idermis: PAD1–3. In agreement, only PAD1–3 activities were
detected in newborn mouse skin (Terakawa et al, 1991). But
PAD2 was not immunodetected by Urano et al (1990) in
human epidermis, using a serum directed against rat-PAD2
(Urano et al, 1990). This is probably because of epitope
masking caused by the acetone fixation step performed in
this work. PADI4 was also reported to be expressed in rat
(Yamakoshi et al, 1998) and mouse epidermis (Rus’d et al,
1999), but only at the mRNA level. This discrepancy could
Figure 6
Immunofluorescence staining of peptidylargi-
nine deiminase isoforms (PAD)2 in human ep-
idermis. Normal human skin cryosections were
analyzed by confocal microscopy using the anti-
PAD2 (C2) antibodies, the anti-desmoglein 1
and 2 (DSG1–2) monoclonal antibody, DG3.10,
and the anti-(pro)filaggrin monoclonal antibody,
AHF3, as indicated. Image superimpositions
of DSG1–2/PAD2 and pro(filaggrin)/PAD2 are
shown. Scale bar: 40 mm (E–G), 20 mm (A–C),
10 mm (H), 5 mm (D).
Figure 7
Immunofluorescence staining of peptidylargi-
nine deiminase isoforms (PAD)3 in human ep-
idermis. Normal human skin cryosections were
analyzed by confocal microscopy using the
anti-PAD3 (B3) antibodies, the anti-desmoglein 1
and 2 (DSG1—2) monoclonal antibody, DG3.10,
and the anti-(pro)filaggrin monoclonal antibody,
AHF3, as indicated. Image superimpositions
of DSG1–2/PAD3 and pro(filaggrin)/PAD3 are
shown. Scale bar: 40 mm (E–G), 20 mm (A–C),
10 mm (D), 5 mm (H).
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be easily explained by blood cell contamination or may
reflect a difference between species. For the first time,
we characterized PAD2 in human and mouse epidermis, as
a 76 kDa protein. Human epidermal PAD3 appeared as a
single band of 70 kDa, as was observed for the recombinant
and human hair follicle PAD3 (Kanno et al, 2000). Mouse
PAD3 size at 80 kDa is similar to the value reported for the
sheep enzyme (Rogers et al, 1997).
Why does epidermis express several isoforms of PAD
and when are they produced in the tissue during keratin-
ocyte differentiation? We investigated, by indirect IF and
confocal microscopy, with our specific anti-PAD antibodies
the tissue and cellular localization of the three human ep-
idermal PAD. We demonstrated that PAD1 is present in the
entire epidermis, including the SC as evidenced by western
blotting of superficial SC extracts. The absence of detection
of PAD1 in the SC by immunohistology analysis is probably
because of the well-known epitope masking in this compact
cell layer. PAD2 was detected in all layers of living keratin-
ocytes with a gradient of expression increasing from the
basal (very low detection) to the granular layer, where the
protein was shown to be located at the cell periphery,
probably at/under the plasma membrane. Possible N-my-
ristoylation sites, described to be involved in membrane
attachment (Farazi et al, 2001), were predicted from com-
putational analysis not only for PAD2 but for all five PAD
isoforms. This result disagrees with the previously reported
uniform expression and cytoplasmic location of PAD2 (Is-
higami et al, 2002). In the latter work, however, polyclonal
antibodies raised against the entire recombinant human
PAD2 were used without checking possible cross-reactivity
with the other PAD. In our work, PAD3 expression was re-
stricted to the granular layer and lower SC. This observation
is in apparent discrepancy with a previous immunohisto-
logical study that reported very weak expression in all the
living layers of human epidermis (Kanno et al, 2000). A likely
explanation is that the treatment performed by Kanno and
coworkers with sodium citrate buffer to unmask antigenic
sites on fixed sections might have produced artifacts. Al-
ternatively, the anti-PAD3 antibodies used could cross-react
with another epidermal protein. The similar expression and
location patterns of PAD in human and mouse epidermis
suggest the same substrates and physiological roles in the
two species.
The distribution of PAD from the basal to the granular
layers contrasts with the distribution of deiminated proteins,
only immunodetected in the cornified layer (Senshu et al,
1995, 1996; Ishida-Yamamoto et al, 2002). These data
Figure 8
Immunodetection and location of peptidylarginine deiminase iso-
forms (PAD)1–3 in mouse epidermis. (A) A TE-NP40 extract of adult
mouse epidermis (40 mg of protein) was separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and immunodetected with
the anti-PAD1, anti-PAD2 (C2), anti-PAD3 (B3), and anti-PAD4 antibod-
ies. The position of molecular mass markers is indicated on the left. (B)
Unfixed cryosections of newborn mouse skin were analyzed with the
anti-PAD1, anti-PAD2 (C2), and anti-PAD3 (B3) antibodies by indirect IF.
Note that we usually observed a thick stratum corneum. SB, stratum
basale; SS, stratum spinosum; SG, stratum granulosum; SC, stratum
corneum. Scale bar: 20 mm.
Figure9
Filaggrin deimination by peptidylarginine deiminase isoforms
(PAD)1 and 3. Filaggrin was incubated for 19 h at 501C in the pres-
ence of 10 mM CaCl2 with and without () either recombinant human
PAD1 or 3, as indicated; then it was immunodetected with AHF5, an
monoclonal antibody specific for (pro)filaggrin. The position of molec-
ular mass markers is indicated on the left.
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suggest that PAD are activated during the final stages of
keratinocyte differentiation, e.g., by the calcium gradient
that exists between the lower and the upper layers in the
epidermis (Mauro et al, 1998).
Interestingly, PAD are differentially expressed in the ep-
idermis. A question arising is ‘‘What is the role of PAD2
at the plasma membrane whereas the known deiminated
proteins, filaggrin, and cytokeratins, present a cytoplasmic
location?’’ This suggests that PAD2 is not involved in the
deimination of these proteins but might preferentially act on
particular, yet unidentified, substrates located at the cell
periphery. Used in immunohistological studies, an antibody
against the deiminated human K1 that reacts specifically
with the modified but not with the unmodified protein did
not stain the inner but stained the superficial SC (Ishida-
Yamamoto et al, 2002). This suggested the presence of an
active PAD in the upper SC. In extracts of superficial SC, we
only detected PAD1. Since PAD1 seems to modify K1
in vitro more rapidly than the other PAD (Senshu et al,
1999a), we propose PAD1 as the best candidate in the de-
mination of this keratin in the cornified layer. It is still unclear
as to which PAD contribute to the deimination of filaggrin,
but the co-location of PAD1, 3, and (pro)filaggrin in the
granular layer and lower SC suggests that a single enzyme
or the combination of the two enzymes might be involved in
the process. The deimination of human filaggrin with re-
combinant PAD1 and 3 that we observed in vitro supports
this suggestion. On the other hand, PAD3 could also be
involved in the deimination of trichohyalin since these two
proteins are co-localized in hair follicles, and trichohyalin is
a substrate for PAD3 in vitro (Kanno et al, 2000).
We showed that PAD1 and 2 extracted from human ep-
idermis bind onto immobilized STI in the presence of cal-
cium, as described previously for PAD2 from rabbit skeletal
muscle (Takahara et al, 1983, 1986). In contrast, PAD3 does
not show any affinity toward STI. Therefore, STI-agarose
affinity chromatography should be a useful tool to purify
epidermal PAD1 and 2.
The production of anti-PAD-specific antibodies allowed
us to characterize PAD expression in the epidermis. They
are now used to define the PAD expression pattern in skin
appendages, more particularly, in hair follicles (manuscript
in preparation). They will also be good tools to investigate
whether PAD expression is altered in the psoriatic hyper-
proliferative epidermis and in bullous congenital ichthyosi-
form erythroderma where a decrease and alteration of
protein deimination have been observed (Ishida-Yamamoto
et al, 2000, 2002) as well as in other diseases, particularly in
multiple sclerosis and rheumatoid arthritis.
Materials and Methods
Analysis of mRNA expression by RT-PCR Human multiple tis-
sue cDNA panels I and II (BD Bioscience, Erembodegem,
Belgium), human skin cDNA (Invitrogen, Gibco Invitrogen, Carls-
bad, California), and human epidermis cDNA obtained as de-
scribed previously (Guerrin et al, 2003) were used as templates for
PCR analysis with specific PADI2–4 primer pairs. The primers were
designed in the 30 region of the corresponding cDNA and checked
for absence of homology with any of the reported sequences of the
other PADI cDNA using Blast (Altschul et al, 1990). The primers
used and the expected sizes of the amplified fragments are shown
in Table II. cDNA obtained from cultured HL-60 cells and tested for
the absence of genomic contamination was used as control. PCR
reactions were performed in 25 mL using 0.75 U of Goldstar Taq
DNA Polymerase (Eurogentec, Seraing, Belgium) with the supplied
buffer, 1.5 mM MgCl2, 0.25 mM of each dNTP, 7.5 pmol of each
primer, and 1–2.5 mL of each cDNA sample. The PCR conditions
were as follows: 941C for 3 min, followed by 38 cycles of dena-
turation at 941C for 25 s, annealing at either 571C (PADI2 and 4) or
601C (PADI3) for 20 s, and elongation at 721C for 40 s, followed by
a final elongation at 721C for 5 min. Glyceraldehyde-3-phosphate
dehydrogenase primers were used in PCR control reactions ac-
cording to the manufacturer’s procedure.
Cloning of human PADI4 cDNA, and production of recombin-
ant PAD The full-length PADI4 cDNA was amplified with primers
(Table II) derived from the published sequence (GenBank acces-
sion number AB017919). The PCR reaction was performed in 50 mL
using 1.5 mL of Advantage II Taq polymerase (BD Bioscience), with
the supplied MgCl2 containing buffer, 0.2 mM of each dNTP,
7.5 pmol of each primer, and 1 mL of cDNA. The PCR conditions
were as follows: 941C for 3 min followed by 35 cycles of dena-
turation at 941C for 30 s, annealing and elongation at 681C for 3
min, and a final elongation at 721C for 10 min. The purified PCR
fragments were subcloned into pCRII-TOPO (Invitrogen) and totally
sequenced by a dideoxynucleotide chain termination method us-
ing a Thermo Sequenase fluorescent-labelled primer cycle se-
quencing kit (Amersham Biosciences Europe GmbH, Saclay,
France) and an automated DNA sequencing system. Top10
Escherichia coli strain (Invitrogen) transformed with the con-
structed plasmid was cultured to produce crude extracts contain-
ing recombinant PAD4. A negative control corresponded to a
construction with the cDNA in the reverse orientation.
Table II. Primers used for RT-PCR or full cDNA cloning
Sequence
Pro-
duct
length
(bp)
Primers for PCR
PADI2
Sense 50-ATGCACCTTCATCGACGACATTT-30 332
Antisense 50-TTTCAGCAGGGACAGAGTCGAG-30
PADI3
Sense 50-CAGAGACAGGCCCTGAACGATAA-30 477
Antisense 50-AAGATGGTTCCGCCCTGATCTAA-30
PADI4
Sense 50-TCTTGTGAATATTGTGGCTCCCT-30 133
Antisense 50-AGAGCAGAACTGAGTGTGCAGTG-30
G3PDH
Sense 50-TGAAGGTCGGAGTCAACGGATTTGGT-30 983
Antisense 50-CATGTGGGCCATGAGGTCCACCAC-30
Primers for full cDNA cloning
PADI4
Sense 50-CCGACGATGGCCCAGGGGACATTGAT-30 2000
Antisense 50-GCTCAGGGCACCATGTTCCACCACTT-30
G3PDH, glyceraldehyde-3-phosphate dehydrogenase; PAD, pep-
tidylarginine deiminase isoforms.
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Production of recombinant human GST-PAD1 and 3 was as re-
ported previously (Kanno et al, 2000; Guerrin et al, 2003). Recom-
binant human PAD1 was produced and purified according to the
strategy described for PAD3 by Kanno et al (manuscript in prep-
aration).
Antibodies The characteristics of the antibodies used in this
study are summarized in Table I. The anti-(pro)filaggrin MoAb AHF3
and AHF5 were produced and characterized in our laboratory (Si-
mon et al, 1995). DG3.10, a MoAb directed to DSG1 and DSG2,
was purchased from Progen Biotechnik GmbH (Heidelberg,
Germany). The characterization of the anti-PAD1 antibodies has
already been reported (Guerrin et al, 2003).
Antisera to PAD2–4 were elicited in rabbits by the injection of
synthetic peptides conjugated via an added N-terminal or C-ter-
minal cysteine residue to keyhole-limpet hemocyanin as described
previously (Guerrin et al, 2003). The peptides, shown in Table III,
were synthesized according to the predicted amino acid sequence
of each PAD. In a first step, each antiserum was affinity-purified on
a mixture of the corresponding three peptides coupled to an ag-
arose-activated affinity column (Sulfolink kit), essentially as de-
scribed by the manufacturer (Pierce Chemical). Then, the antisera
to PAD2 and 3 were affinity-purified on the peptide 514–527 (pep-
tide C2) and 49–63 (peptide B3), respectively. The purified anti-
peptide antibodies were stored at 801C. For control experiments,
pre-immunized sera were obtained from each rabbit.
Extraction of proteins from mouse epidermis and from human
epidermis and superﬁcial SC All described studies concerning
human tissues/subjects were conducted in adherence with the
Declaration of Helsinki Principles, and in accordance with the eth-
ical guidelines of the University of Toulouse III and of the French
Ministry of Research and Technology. Breast skin was obtained
from patients undergoing plastic surgery without any history of
skin diseases, following their informed consent. Dermo-epidermal
cleavage was performed by heat treatment as previously de-
scribed (Simon et al, 1997). The epidermis was sequentially ex-
tracted in equal volumes of a Tris-EDTA buffer (40 mM Tris-HCl (pH
7.5), 10 mM EDTA, and protease inhibitors) containing 0.5% Non-
idet P-40 (TE-NP40 buffer extract), 6 M urea (TEU buffer extract) or
6 M urea, and 50 mM dithiothreitol (TEUDTT buffer extract). The
epidermis of B6/CBA adult mice was extracted in TE-NP40 buffer
after dermo-epidermal cleavage performed by heat treatment. All
procedures were performed according to the conventional princi-
ples for animal care.
Superficial SC extracts were obtained from six informed volun-
teers using tape stripping (Lundstro¨m et al, 1994). Proteins were
solubilized in TE-buffer supplemented with 2% SDS and 50 mM
DTT as previously reported (Guerrin et al, 1998). Protein concen-
tration was measured using the Bio-Rad protein assay (Bio-Rad
Laboratories GmbH, Munich, Germany).
HL-60 granulocytes cultured with 1 mM all-trans-retinoic acid for
3 d, as described previously (Nakashima et al, 1999), were directly
lysed in SDS sample buffer.
Protein electrophoresis, immunoblotting, and adsorption ex-
periments Recombinant proteins, rabbit muscle PAD2 (Sigma-
Aldrich), epidermal proteins, and HL-60 extracts were separated
by SDS-PAGE, stained with Coomassie blue or electrotransferred
to reinforced nitrocellulose membranes. The membranes were
stained with Ponceau Red and incubated overnight at 41C with
anti-peptide antibodies.
To analyze recombinant or purified PAD and protein extracts,
anti-PAD antibodies were diluted to 1/10,000 and 1/200, respec-
tively, in Tris-buffered saline (20 mM Tris-HCl, pH 7.5, 0.15 mM
NaCl) supplemented with 2.5% skimmed milk powder and 0.05%
Tween-20. Then, the membranes were probed with 1/10,000
dilution of horseradish peroxidase-conjugated anti-rabbit IgG sec-
ondary antibody (Zymed Laboratories, California), and immuno-
detection was performed with the ECL western blotting kit as
described by the manufacturer (Amersham Biosciences). For
adsorption experiments, the antibodies anti-PAD2, anti-PAD3,
and anti-PAD4, diluted to 1/10,000 or anti-PAD2 (C2) and anti-
PAD3 (B3) diluted to 1/200, were pre-adsorbed for 30 min at 371C
with peptides at 20 mg per mL.
Enrichment of PAD by afﬁnity chromatography on a column of
immobilized STI A TE-NP40 buffer extract of human epidermis
was diluted in one volume of 2-fold concentrated buffer B (40 mM
Tris-HCl (pH 7.5), 10% glycerol, 0.1 M NaCl, 10 mM 2-me-
rcaptoethanol, 10 mM DTT) containing 20 mM CaCl2, and applied
to a column of STI-agarose (Pierce Chemical) as described pre-
viously (Takahara et al, 1986). The column was washed with buffer
B containing 10 mM CaCl2, and adsorbed proteins were eluted
with buffer B containing 10 mM EGTA.
Immunohistology Indirect IF was performed on unfixed 5–7 mm
thick cryosections of human and newborn mouse skin. After re-
hydration in PBS at room temperature, sections were incubated in
a moist chamber for 30 min with PBS containing 1% bovine serum
albumin (BSA) and 0.05% Tween-20, and then overnight at 41C
with the anti-peptide antibodies diluted in the same buffer (anti-
PAD1 and anti-PAD3 (B3) to 1/10, and anti-PAD2 (C2) to 1/25). After
washing four times in PBS containing 0.05% Tween-20, sections
were incubated for 1 h at room temperature with fluorescein is-
othiocyanate-labelled goat anti-rabbit IgG (Hþ L) (Zymed Labora-
tories) diluted to 1/250 in PBS containing 1% BSA and 0.05%
Tween-20.
In the case of double staining, the sections were further incu-
bated for 1 h at 371C with MoAb AHF3 or DG3.10 diluted to 2.5 mg
per mL. After washing four times in PBS containing 0.05% Tween-
20, sections were incubated for 1 h at room temperature with tet-
ramethyl rhodamine isothiocyanate-conjugated, F(ab0)2 fragments,
goat anti-mouse IgG (Immunotech, Marseille, France) diluted to
1/200 in PBS containing 1% BSA and 0.05% Tween-20. Sections
were washed in PBS and finally mounted in an anti-fading solution
(Mowiol, Calbiochem, La Jolla, California) before observation under
a confocal laser microscope (LSM 410, Carl Zeiss, Oberkochen,
Table III. Peptides used for antibody production
Peptides Sequence
Amino
acid
position
GenBank
accession
number
Anti-PAD1
Peptide A1 CMAPKRVVSQLSLKM 1–13
Peptide B1 CNHRSAEPDLTHSWLM 158–172 AB033768
Peptide C1 CARGGNSLSDYKQ 215–227
Anti-PAD2
Peptide A2 MLRERTVRLQYGSC 1–13
Peptide B2 CTPWLPKEDMRDEK 159–171 AB030176
Peptide C2 MFKGLGGMSSKRITC 514–527
Anti-PAD3
Peptide A3 MSLQRIVRVSLEHC 1–13
Peptide B3 DIYISPNMERGRERADTRC 49–66 AB026831
Peptide C3 CEAYRHVLGQDKV 223–235
Anti-PAD4
Peptide A4 MAQGTLIRVTPEQC 1–13
Peptide B4 VVDIAHSPPAKKKSTC 49–63 AB017919
Peptide C4 FQATRGKLSSKC 214–225
PAD, peptidylarginine deiminase isoforms.
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Germany), excited at 488 and 543 nm with Ar and HeNe lasers,
respectively. For negative controls, sections were incubated with-
out primary antibodies.
Filaggrin deimination Filaggrin was enriched from an epidermal
extract in 6 M urea on a HiTrapQ ion exchange column (Amersham
Biosciences) as previously reported (Lynley and Dale, 1983). Frac-
tions containing filaggrin were dialyzed, incubated (100 ng per
test) in a deimination buffer containing 10 mM CaCl2 without or
with either recombinant human PAD1 or 3 for 19 h at 501C, and
immunodetected with AHF5 (0.4 mg per mL).
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